Details of the Drug Reposition

General Information of This Drug (ID: DMLYIPA)

Drug Name
SGT-53   DMLYIPA
Synonyms P53 gene stimulator (solid tumor), Synergene Therapeutics
Drug Type
Gene therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Recurrent glioblastoma DISHYPKS 2A00.00 Phase 2 [1]
Pancreatic cancer DISJC981 2C10 Phase 2 [2]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02340156) Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT02354547) A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors. U.S. National Institutes of Health.